

# Barbara ZiÅ³kowska

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3874051/publications.pdf>

Version: 2024-02-01

8  
papers

41  
citations

1937685  
4  
h-index

1872680  
6  
g-index

8  
all docs

8  
docs citations

8  
times ranked

87  
citing authors

#	ARTICLE	IF	CITATIONS
1	Development of immunity-related adverse events correlates with baseline clinical factors, survival and response to anti-PD-1 treatment in patients with inoperable or metastatic melanoma. <i>Journal of Dermatological Treatment</i> , 2022, 33, 2168-2174.	2.2	5
2	Systemic treatment in patients with malignant pleural mesothelioma – real life experience. <i>BMC Cancer</i> , 2022, 22, 432.	2.6	2
3	First-line treatment of advanced/metastatic melanoma with anti-PD-1 antibodies: multicenter experience in Poland. <i>Immunotherapy</i> , 2021, 13, 297-307.	2.0	6
4	Comparison of the efficacy and toxicity of anti-PD-1 monoclonal antibodies (nivolumab versus) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 62. <i>2021</i> , 39, e21514-e21514.	1.6	2
5	Anti-programmed cell death-1 therapy in octogenarian and nonagenarian advanced/metastatic melanoma patients. <i>Melanoma Research</i> , 2021, 31, 49-57.	1.2	4
6	Predictive value of quantitative HER2, HER3 and p95HER2 levels in HER2-positive advanced breast cancer patients treated with lapatinib following progression on trastuzumab. <i>Oncotarget</i> , 2017, 8, 104149-104159.	1.8	8
7	Co-expression of autophagic markers following photodynamic therapy in SW620 human colon adenocarcinoma cells. <i>Molecular Medicine Reports</i> , 2016, 14, 2548-2554.	2.4	8
8	Immunohistochemical prediction of lapatinib efficacy in advanced HER2-positive breast cancer patients. <i>Oncotarget</i> , 2016, 7, 550-564.	1.8	6